Jefferies maintains Hollis-Eden at hold

Hollis-Eden Pharmaceuticals Inc. was maintained by Jefferies & Co. Inc. analyst Adam A. Walsh at a hold rating after the Department of Health and Human Services issued a final request for proposals for the procurement of drugs (Neumune) to treat Acute Radiation Syndrome. The government is unchanged in its view to procure 100,000 treatment courses. Previously, it said it could request 100,000 more, and the company still is lobbying for the government to adjust the final RFP to solicit a larger amount of the drug that fits the Neumune profile. Shares of the San Diego pharmaceutical company were down 21 cents, or 4.05%, at $4.97 on volume of 566,094 shares versus the three-month running average of 422,166 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.